AnaptysBio (ANAB) News Today

AnaptysBio, Inc. (NASDAQ:ANAB) shares moved today amid a flurry of analyst rating changes and earnings-forecast revisions.

• Positive Sentiment: Analyst upgrade lifts ANAB nearly 9%. AnaptysBio Trading Up 8.9% on Analyst Upgrade
• Positive Sentiment: Leerink Partnrs raised Q4 2025 EPS to $1.04 from ($0.67), pointing to stronger late-year results.
• Positive Sentiment: Leerink Partnrs narrowed FY 2025 loss estimate to ($1.69) from ($3.97), cutting expected annual losses.
• Positive Sentiment: Leerink Partnrs improved FY 2028 outlook to ($1.87) from ($2.14) and FY 2029 to ($0.82) from ($0.92), signaling incremental progress toward profitability.
• Positive Sentiment: HC Wainwright lifted Q4 2025 EPS to ($1.62) from ($1.66), and boosted longer-term forecasts—FY 2026 to ($6.35) from ($8.15), FY 2028 to ($3.94) from ($9.83) and FY 2029 to ($1.88) from ($7.84)—while maintaining a Buy rating and $59 target.
• Neutral Sentiment: Guggenheim reiterated its Buy rating on ANAB without changing its outlook. Guggenheim Sticks to Their Buy Rating
• Negative Sentiment: Leerink Partnrs cut Q3 2025 EPS to ($0.85) from ($0.84), and trimmed FY 2027 and FY 2026 forecasts to ($3.01) from ($2.66) and to ($2.98) from ($1.18), respectively, indicating softer near-term profitability. Leerink Partnrs Decreases Earnings Estimates
• Negative Sentiment: HC Wainwright lowered Q3 2025 EPS to ($1.59) from ($1.51) and trimmed FY 2025 to ($5.82) from ($5.78), dampening short-term earnings visibility.
• Negative Sentiment: A “Time to Sell?” report followed a 5.9% share-price drop, underscoring investor caution ahead of upcoming data. ANAB Stock Price Down 5.9% - Time to Sell?